SYDNEY, February 10, 2026, 17:17 AEDT
CSL shares slid 4.98% Tuesday after the Australian biotech announced CEO Paul McKenzie’s retirement and tapped director Gordon Naylor as interim chief, effective Feb. 11. The S&P/ASX 200, which spent much of the day in positive territory, ended almost flat—off 0.03% at 8,867.4. 1
The timing isn’t ideal. Just as investors begin dipping back into risk following last week’s steep, tech-led drop, CSL drops its update—landing right ahead of the company’s results.
Monday saw the ASX 200 surge 1.9%, erasing last week’s 1.8% slide. Miners, property shares out front, and tech stocks found their footing too. NextDC and Megaport—both data-centre players—each advanced roughly 5%. 2
The Nasdaq picked up 0.90% overnight in New York, with the S&P 500 up 0.47%, according to Reuters, as tech stocks bounced back after last week’s AI-driven selloff. Nvidia climbed 2.5%. “You’ve a sharply oversold market where a little bit of good news can go a long way,” noted Keith Lerner of Truist Advisory Services. Wall Street is now eyeing Wednesday’s U.S. payrolls data and Friday’s CPI figures. 3
CSL chair Brian McNamee said in a statement that the board, along with outgoing CEO Paul McKenzie, agreed “now is the right time for new leadership” amid the company’s ongoing strategic transformation. The company has launched a search for a new chief executive. Interim CEO Paul Naylor described his “immediate priority” as collaborating with the board and executive team. McKenzie, meanwhile, called his tenure as CEO “a privilege.” McNamee and Naylor are scheduled to hold an investor call at 5:00pm AEDT.
CSL brought McKenzie on board as chief operating officer back in 2019. By March 2023, he’d stepped into the CEO and managing director roles, according to Reuters. Now, with McKenzie set to leave, ex-finance chief Gordon Naylor is stepping in as interim leader. CSL’s therapies include HEMGENIX, a gene therapy targeting haemophilia B by delivering genetic material to combat the disease. 4
CSL’s drop highlighted just how quickly earnings season can turn sour—even if the broader index barely budges. Sometimes, it only takes a heavyweight to jolt the market.
Still, risk appetite seems fragile. A stronger U.S. inflation number—or fresh selling in the megacap tech names—could quickly spill over to local markets, likely overwhelming any company-specific moves.
